3 Amendments of Krišjānis KARIŅŠ related to 2017/2179(DEC)
Amendment 21 #
Motion for a resolution
Paragraph 16
Paragraph 16
16. Notes that, according to the Court’s summary, public procurement remains an error-prone area; notes that EASO, the European Monitoring Centre for Drugs and Drugs Addiction (EMCDDA), the European Agency for the operational management of large-scale IT Systems in the area of freedom, security and justice (eu-LISA), the European Medicines Agency (EMA) and the Body of European Regulators for Electronic Communications (BEREC) did not fully comply with the public procurement principles and rules laid down in the Financial Regulation; calls on the Agencies to pay particular attention to the Court’s comments on public procurement;
Amendment 36 #
Motion for a resolution
Paragraph 26
Paragraph 26
26. Observes that decentralised agencies increased the use of contract staff by 718 full-time equivalents to implement new tasks, in partial compensatation for the 5 % staff cut and the levy for the creation of the redeployment pool; notes that this mostly concerns Frontex, Europol, EASO and EASA, the European Union Agency for Network and Information Security (ENISA) and the European Global Navigation Satellite Systems Agency (GSA); is of the opinion that the use of contract staff is not in line with the targets set to achieve the staff reductions and should be used only as a temporary measure, in agencies with the greatest demand for new staff due to an increase in workload; calls on the Commission to deliberate again on its plans for a further 1 % annual staff reduction;
Amendment 46 #
Motion for a resolution
Paragraph 37
Paragraph 37
37. Notes that, according to the Court’s summary, the external evaluations of the agencies are in general positive and agencies prepared action plans to follow up issues raised in the evaluation reports; notes that while most agencies’ founding regulations provide for an external evaluation to be carried out periodically (usually every four to six years), the founding regulations of fivesix decentralised agencies - BEREC Office, EASO, eu- LISA, ETF, ENISA and European Institute for Gender Equality - do not include such a provision and the founding regulation of the European Medicines Agency (EMA) requires an external evaluation only every ten years; is of the opinion that this issue should be addressed;